Description

Gersizangitide (AXT-107) is an angiogenesis inhibitor[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)–Cancer-programmed cell death–C111H167N29O28—-[1]WHO Drug Information, Vol. 35, No. 4, 2021. Geneva: World Health Organization; 2022.–2417491-82-6–2355.69–98.05–NC([C@H](CC1=CC=CC=C1)NC([C@H](CC(N)=O)NC([C@H]([C@@H](C)CC)NC([C@H](C(C)C)NC([C@H](CC(O)=O)NC([C@H](CC(N)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CC(O)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CC2=CC=CC=C2)NC([C@H](C)NC([C@H](CC3=CC=CC=C3)NC([C@H]4N(CCC4)C([C@H](C)NC([C@H]([C@H](O)C)NC([C@H](CO)NC([C@@H](NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC([C@@H](N)CC(C)C)=O)=O)=O)CC5=CC=CC=C5)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O–Cancer–H2O : 33.33 mg/mL (ultrasonic)–Others—-Others–Peptides